🔗 Share this article

While the United States undertakes historic adjustments to its immunization schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning COVID-19 shots throughout the global health crisis and has zeroed in on alleged deaths following COVID-19 immunization in her recent time at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities planned to reveal sweeping changes to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with much of the international standard with little proof for public health gain. The announcement has been postponed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine branches as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric shot schedules in the US so as to align more like Denmark's approach, a nation with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – usually the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no obvious track record in pharmaceutical research, approval processes or leadership, which has been customary for past heads of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a major agency. She has no expertise in drug approvals.”

Previous heads of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Clearly, she lacks the kind of background that former directors who led CBER have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“Many people just pays attention on the new drug program, but the generic program clears thousands of generic medications. There is also a biosimilars program, over-the-counter program and other areas, and each of these have to be looked after,” she noted. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership component to the position, which supervises over 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among agency officials on vaccines, a spokesperson stated that the “concerns stem from flawed assumptions”.

“Her experience matches the duties of her position,” the representative said, noting the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched expedited review system, a contentious one-day therapy clearance system that allegedly troubled her predecessors. “By what process are these medications being selected for this expedited pathway? Who makes the choices?” Howard said. “There is a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent oversight of all drugs, aside from immunizations.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, track record, Howard have noted. She published a research paper using non-validated volunteer-provided data to determine the rate of heart inflammation following Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are riskier than they are.

Included in her “policy goals” for the incoming government included altering rules for new vaccines and ending “unnecessary” vaccines, she remarked following the vote on a podcast. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from getting COVID-19 vaccines.

“She is an complete true believer who starts off with her preconceived notions and tailors the evidence to fit the data in a very misleading, dishonest way,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|